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Cefotaxime sodium 45.5 (1 g div)a 0.90 (1 g div)a 59.5% (div 6 h)a AUC: 82.6 (1 g iv)a
Ceftizoxime sodium 57.9 (1 g div) 1.33 (0.5 g iv) 80–90% (iv 6 h) AUC: 113.8 (1 g div)a
Cefmenoxime
hydrochloride
50.9 (1 g div) 1.05 (1 g div) 60–82% (div 6 h) AUC: 82.8 (1 g div)a
Cefodizime sodium 96.1 (1 g div)a 2.43 (1 g div) 69% (1 g iv 8 h) AUC: 308 (1 g div)a
Ceftriaxone sodium 122.2 (1 g div)a 7.1 (1 g div) 50% (1 g div 24 h) AUC: 1,058 (1 g div)a,
protein binding rate:
83–96%
Cefoperazone sodium 125 (1 g div) 2.67 (1 g div) 26–36% (div 6 h) Protein binding rate:
86.8%a
Cefpiramide sodium 215 (1 g div) 4.52 (1 g div) 23% (div 24 h) AUC: 490 (0.5 g iv)a
Ceftazidime 69.3 (1 g div) 1.64 (1 g div) 74–86% (div 6 h) AUC: 144 (1 g div)
Cefpirome sulfate 57.0 (1 g div)a 1.70 (1 g div) [80% (div 24 h) AUC: 138 (1 g div)
Cefepime dihydrochloride 79.7 (1 g div)a 1.76 (1 g div) 83% (1 g div 24 h) AUC: 158 (1 g div)a
Cefozopran hydrochloride 68.3 (1 g div) 1.59 (1 g div) 72–85% (div 6 h) AUC: 180 (1 g div)a
Cephamycins and oxacephamycins
Cefmetazole sodium 76.2 (1 g div) 1.2 (div) 85–92% (div 6 h) Protein binding rate:
84–85%
Cefbuperazone sodium 119.2 (1 g div)a 1.82 (1 g div) 80% (div 12 h) AUC: 197.7 (1 g iv)a,
protein binding rate:
55%a
Cefminox sodium 98.4 (1 g div) 2.48 (1 g div) 80% (1 g div 6 h) AUC: 292.8 (1 g div)a,
protein binding rate:
61%
Latamoxef sodium 77.2 (1 g div) 2.21 (1 g div) 74–83% (div 6 h) Protein binding rate: 60%
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Benzylpenicillin potassium 5.73 (IU/mL) (400
thousand IU im)
– 49.3% (im 3 h) –
Piperacillin sodium 60.2 (1 g div) 0.78 (1 g div) 56.2% (1 g div 24 h) AUC: 47.9, protein
binding rate: 21.2%
85.8 (2 g div) 0.79 (2 g div) – AUC: 111.6, protein
binding rate: 21.2%




Imipenem/cilastatin sodium 40.10 (0.5 g div, 0.5 h) 0.97 (0.5 g div, 0.5 h) 72.8% (0.5 g div, 12 h) AUC: 41.37 (0.5 g div,
0.5 h)a
Panipenem/betamipron 26.24 (0.5 g div) 1.27 (0.5 g div) 30% (0.5 g div, 24 h) AUC: 40.27 (0.5 g div)
Meropenem 26.9 (0.5 g div, 0.5 h) 1.03 (0.5 g div, 0.5 h) 60–65% (div 8 h) AUC: 33.9 (0.5 g div,
0.5 h)
Biapenem 17.3 (0.3 g div) 1.03 (0.3 g div) 63.4% (0.3 g div, 12 h) AUC: 29.2 (0.3 g div)
Doripenem 33.1 (0.5 g div, 0.5 h) 0.86 (0.5 g div, 0.5 h) 75% (div 24 h) AUC: 34.38 (0.5 g div,
0.5 h), protein binding
rate: 9%
b-Lactamase inhibitor combination drugs
Sulbactam sodium/
cefoperazone sodium
SBT: 20, CPZ: 62
(1 g div)a
0.5–0.67 SBT: 72.0%, CPZ: 25.3%,
(1 g div)
AUC: SBT; 79.5, CPZ;
235.7 (1 g div)a
Tazobactam sodium/
piperacillin sodium
TAZ: 36.3, PIPC: 28.6
(4.5 g div)a
0.814 71.2% AUC: 47.4
0.868 52.9% AUC: 366
Other antibiotics
Lincomycin hydrochloride 17 (0.6 g div) – 11–13.5% (0.6 g div, 8 h) –
Clindamycin phosphate 10.7 (0.6 g div) – 9.3% (0.6 g div, 6 h) –
Chloramphenicol sodium
succinate
14.9 (1 g iv) 0.7 (1 g iv) – AUC: 73.3 (0–12 h)
Fluoroquinolones












1.5–1.8 (0.1 g) 2.0 40–50% (12 h) Tmax: 3–4 h, AUC: 8.7
(0.1 g), protein binding
rate: 30%
Cefdinir (capsules only) 1.11 (0.1 g) 1.6–1.8 26–33% (24 h) Tmax: 4 h, AUC: 6.16
(0.1 g)a
Cefditoren pivoxil 1.66 (0.1 g) 0.80 (0.1 g) 20% (24 h) Tmax: 1.4 h, AUC: 3.67




1.28 (0.1 g) 1.01 (0.1 g) 40% (24 h) Tmax: 1.3 h, AUC: 3.86
(0.1 g), protein binding
rate: 45%


















6.6 (0.25 g) – 50.4 (6 h) Tmax: 0.75 h
Faropenem sodium
(tablets only)
6.24 (0.3 g) 0.85 (0.3 g) 3.1–6.8% (24 h) Tmax: 1.04, AUC: 11.73
(0.3 g)
b-Lactamase inhibitor combination drugs
Potassium clavulanate/
amoxicillin
CVA: 2.86, AMPC: 4.88
(0.375 g)
1.0 CVA: 35%, AMPC: 67%
(0.375 g 8 h)




Erythromycin (tablets only) 1.25 (0.4 g) – – Tmax: 3–4 h
Erythromycin stearate 0.82 (0.2 g) – \5% Tmax: 2.8 h, protein
binding rate: 64.5%




1.16 (0.2 g) 4.04 (0.2 g) 40–50% (24 h) (including
active metabolites)
Tmax: 1.9 h, AUC: 8.98
(0.2 g)
Telithromycin 0.91 (0.6 g) 9.6 (0.6 g) – Tmax: 2.5 h, AUC: 4.0
(0.6 g), protein binding
rate: 60–70%
Azithromycin (250 mg
tablets, 2 g sustained-
release formulation)
0.58 (0.5 g) 61.9 (0.5 g) 9% (168 h) Protein binding rate:
12.3–20.3%
Rokitamycin 0.49 (0.2 g) 2.0 (0.2 g) \2% (24 h) Tmax: 0.5 h













\detectable limit – Not detected. Eliminated via
feces: 2.5–4.8 mg/g
(0.5 g serial treatment)
–
Chloramphenicol
(tablets and powders only)
7.2 (0.5 g) – – Tmax: 1.9 h, AUC:
36.3% (0.5 g 12 h),
protein binding rate:
57%
Chloramphenicol palmitate – – – –
Fluoroquinolones
Oﬂoxacin (tablets) 1.65 (0.2 g) 4.50 (0.2 g) [90% (48 h) Tmax: 3.0 h, AUC: 21.7




8.04 (0.5 g) 7.89 (0.5 g) 83.76% (72 h) Tmax: 0.99 h, AUC:








1.89 (0.2 g) 8.48 (0.2 g) 80.6% (72 h) Tmax: 1.23 h, AUC:
13.97 (0.2 g)















Tosuﬂoxacin tosilate 0.54 (0.15 g) 4.85 (0.15 g) 45.8% (24 h) Tmax: 2.00 h, AUC: 4.95
(0.15 g)
Fleroxacin 1.33 (0.1 g) 10.4 (0.1 g) 72–79% (72 h)a Tmax: 2.3 h, AUC: 16.59
(0.1 g)
Sparﬂoxacin 0.62 (0.2 g) 15.8 (0.2 g) 12% (72 h), eliminated via
feces: 51% (72 h)
Tmax: 3.5 h, protein
binding rate: 42.2%
Pruliﬂoxacin 1.09 (0.2 g) (as active
metabolite)
8.9 (0.2 g) 36.2% (24 h) Tmax: 0.7 h, AUC: 6.41
(0.2 g), protein binding
rate: 50.9–52.1%
Moxiﬂoxacin 4.13 (0.4 g) 13.9 (0.4 g) 19% (96 h), eliminated via
feces: 25% (96 h)
Tmax: 1.75 h, AUC: 51.5
(0.4 g)



















– – – –
Minocycline hydrochloride
(dental ointment only)
In periodontal pocket 0.1






In aqueous humor 1.20
(5 doses, 1 h later)
– – –





















– – – –




2.0 lg/L (1 drop/dose, 8
doses/day, 14 days; day
14, 24 h after ﬁrst dose)
– – –
Note: Unless otherwise speciﬁed, div means 1 h drip infusion
a Quoted from the leaﬂet for the New Drug Symposium of the Japanese Society of Chemotherapy. The other information is quoted from the package
inserts for major products
b AUC (h lg/mL)
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